Literature DB >> 22192654

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.

Dirk Strumberg1, Beate Schultheis, Ulrich Traugott, Christiane Vank, Ansgar Santel, Oliver Keil, Klaus Giese, Jörg Kaufmann, Joachim Drevs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22192654     DOI： 10.5414/cpp50076

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  33 in total

Review 1.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

Review 2.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

Review 3.  Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.

Authors:  J Wu; S Liu; J Yu; G Zhou; D Rao; C M Jay; P Kumar; R Sanchez; N Templeton; N Senzer; P Maples; J Nemunaitis; F C Brunicardi
Journal:  Cancer Gene Ther       Date:  2014-01-24       Impact factor: 5.987

Review 4.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

5.  RNAi therapies: drugging the undruggable.

Authors:  Sherry Y Wu; Gabriel Lopez-Berestein; George A Calin; Anil K Sood
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

6.  Counterion of Chitosan Influences Thermodynamics of Association of siRNA with a Chitosan-Based siRNA Carrier.

Authors:  Christelle Zandanel; Magali Noiray; Christine Vauthier
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

Review 7.  Imaging-guided delivery of RNAi for anticancer treatment.

Authors:  Junqing Wang; Peng Mi; Gan Lin; Yì Xiáng J Wáng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-01-22       Impact factor: 15.470

Review 8.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer.

Authors:  Jonathan E Zuckerman; Mark E Davis
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

9.  Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds.

Authors:  Szu-Ting Chou; Kellie Hom; Daoning Zhang; Qixin Leng; Lucas J Tricoli; Jason M Hustedt; Amy Lee; Michael J Shapiro; Joonil Seog; Jason D Kahn; A James Mixson
Journal:  Biomaterials       Date:  2013-10-22       Impact factor: 12.479

Review 10.  Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

Authors:  Lígia Catarina Gomes-da-Silva; Sérgio Simões; João Nuno Moreira
Journal:  Cell Mol Life Sci       Date:  2013-11-13       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.